Kidney cancer pathology in the new context of targeted therapy. - Wikidata - wikimedia - TriplyDB

Kidney cancer pathology in the new context of targeted therapy.

Kidney cancer pathology in the new context of targeted therapy.

http://www.wikidata.org/entity/Q37890209

about

Heterogeneity and renal mass biopsy: a review of its role and reliability.Attenuation of krüppel-like factor 4 facilitates carcinogenesis by inducing g1/s phase arrest in clear cell renal cell carcinoma Genome-wide analysis of differentially expressed genes and splicing isoforms in clear cell renal cell carcinoma.Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications.Pazopanib: a review of its use in the management of advanced renal cell carcinoma.Loss of PBRM1 expression is associated with renal cell carcinoma progression.Hippo signaling mediates proliferation, invasiveness, and metastatic potential of clear cell renal cell carcinoma.Bilateral renal cell carcinoma with leiomyomatous stroma: A rare entity diagnosed synchronously and treated surgically in a staged fashion.

P2860

Q34340943-C16FBA52-0E4A-4C80-81EC-A97D064068F2 Q34826101-9B77EDAF-A0C3-4658-89C3-951047612AC6 Q35032590-88452B81-29A0-453B-9FA3-709790773C09 Q38087239-AAF77EC9-5CA0-47EE-9C54-15B4C946E35C Q38220728-DFDB8B62-4D7F-4DB3-83D9-33D655D9DA7F Q39285387-22FF2638-FF61-4E05-953B-B78ABF300D54 Q41867443-0C507D99-75AF-49E8-BC9F-E372D5FE1336 Q47110207-C43DE7E5-A7F5-4AC1-93C2-65846B9372F8

P2860

Kidney cancer pathology in the new context of targeted therapy.

http://www.wikidata.org/entity/Q37890209

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 June 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Kidney cancer pathology in the new context of targeted therapy.

@en

Kidney cancer pathology in the new context of targeted therapy.

@nl

type

label

Kidney cancer pathology in the new context of targeted therapy.

@en

Kidney cancer pathology in the new context of targeted therapy.

@nl

prefLabel

Kidney cancer pathology in the new context of targeted therapy.

@en

Kidney cancer pathology in the new context of targeted therapy.

@nl

P1433

Q37890209-C670430B-853A-4AEC-9710-12CDB1F3DA4B

P1476

Q37890209-EE4AB4B7-94FF-424E-A3F2-5CB78AC56C09

P2093

Q37890209-2B5D9BA7-E686-4248-9CC9-36167B59D99A

Q37890209-A6C994CE-3FCD-4A05-BF88-D991B194954E

Q37890209-DD877583-967B-4F29-8400-2A5B94B99117

P2860

Q37890209-0C1AE3CF-6A23-49CC-A6FB-36DB966B32E6

Q37890209-10F01C36-D193-466A-BBCF-327CBEE6B47C

Q37890209-11B49E7D-CB26-41F1-852C-7E8B04BB0AB6

Q37890209-144B3571-E3A3-4DF6-AB38-DDA8C3981683

Q37890209-18BC2B72-6F98-4FB9-BBB1-125D15BC2D3C

Q37890209-1948BDEF-9484-45AB-A613-D788B1CFC47C

Q37890209-28181407-9458-4FD7-8071-FA296BD48A56

Q37890209-287C49D8-B810-4FF1-85F2-4DBF63B9EE9B

Q37890209-2920D6C0-B4E4-4299-8EE4-E1A834798EC3

Q37890209-2A7FDB0E-A76B-4F0E-A62E-8A59A2CC48EB

P304

Q37890209-059A2467-B253-4635-9AFF-C477FA808C0E

P31

Q37890209-0BB44E5F-CE56-43EC-8416-0AF87DCCE0F3

P356

Q37890209-3744371A-731C-434B-99A8-6D4F48B5A401

P433

Q37890209-D00CAE65-F967-4E57-8C86-40BD46869A5E

P478

Q37890209-77706976-DAFE-4066-8F51-8985FB7ABDB6

P577

Q37890209-BB0CA81A-EE75-482A-AC06-ADC309BABEF6

P5875

Q37890209-74D54049-FBAF-4EE6-ADB5-D6B633EECB93

P698

Q37890209-52A0D0CB-9B64-43E9-BA85-F0D2159C65BF

P921

Q37890209-a4e331f2-6e23-4d1d-ac85-c0086586bf64

P932

Q37890209-D895E481-2E41-46FC-8185-5F1ACF18CF76

P356

P1433

P1476

Kidney cancer pathology in the new context of targeted therapy.

@en

P2093

Alexandre de la Taille

http://www.w3.org/2001/XMLSchema#string

Stéphane Culine

http://www.w3.org/2001/XMLSchema#string

Yves Allory

http://www.w3.org/2001/XMLSchema#string

P2860

Fumarase: a mitochondrial metabolic enzyme and a cytosolic/nuclear component of the DNA damage response

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2

c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma

Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2

Renal tumour suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin

Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia

The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis

P304

90-98

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000315543

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

78

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51223227

http://www.w3.org/2001/XMLSchema#string

P698

21677472

http://www.w3.org/2001/XMLSchema#string

P921

P932

3361895

http://www.w3.org/2001/XMLSchema#string